360b / Shutterstock.com
A US appeals court has issued a mixed judgment in a patent dispute that saw Novartis file infringement claims against both Watson Pharmaceuticals and Par Pharmaceutical.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Novartis; US Court of Appeals for the Federal Circuit; Watson Pharmaceuticals; rivastigmine; ANDA; US District Court for the District of Delaware; Par Phar
